A vs NTRA
Agilent Technologies and Natera, Inc., both Healthcare
Agilent Technologies is the larger company at $36B against $33B. Over the past year NTRA returned +140% against +42% for A. Ryufin's sector-relative Smart Score puts NTRA ahead, 10/10 against 8/10.
| Figure | A | NTRA |
|---|---|---|
| Last close | $160 | $339 |
| Market cap | $36B | $33B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 32.2 | n/a |
| Dividend yield | 0.6% | n/a |
| 1-year return | +42% | +140% |
| 5-year return | +8.0% | +201% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 10/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Agilent Technologies
Revenue of $1.8B in Q2 2026, net income $339M. Its largest reported line is Life Sciences And Diagnostics Markets, 48% of the disclosed total.
Natera, Inc.
Revenue of $753M in Q2 2026, net income null. Its largest reported line is US, 98% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.